IMDC (Heng) Metastatic RCC Risk
IMDC (Heng) Metastatic RCC Risk - a deterministic tool in Sophie Well's Clinical Scoring & Risk group.
Open the IMDC (Heng) Metastatic RCC Risk → Runs in your browser. No signup, no tracking.
What this is
IMDC (Heng) Metastatic RCC Risk is one of 230 deterministic tools in Sophie Well's Clinical Scoring & Risk group. IMDC (Heng) Metastatic RCC Risk - a deterministic tool in Sophie Well's Clinical Scoring & Risk group.
When to use it
Use this tool when you need a quick, citable reference. Every calculation runs entirely in your browser - no inputs leave your device, no account is required, no AI is involved. The site enforces a strict Content Security Policy and ships no analytics or third-party CDN.
References
Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents. J Clin Oncol. 2009;27(34):5794-5799. Read the source ↗
Worked example: IMDC: 3 factors — poor risk (median OS 7.8 mo).
Sophie Well is a reference and educational tool. Not medical, legal, or financial advice. Does not replace clinician judgment, professional billing review, or legal counsel.